Key clinical point: Baseline histologic grade was the most important predictor of recurrence after radiofrequency ablation of Barrett’s esophagus.
Major finding: The proposed surveillance intervals were 1 year, followed by 3 years, followed by more than 5 years for patients with completely eradicated low-grade dysplasia. For cases of high-grade dysplasia or carcinoma in situ, the proposed surveillance intervals were 3 months, 6 months, 1 year, and then annually.
Study details: An analysis of data from the United States Radiofrequency Ablation Registry and the United Kingdom National Halo Registry.
Disclosures: The National Institutes of Health and Barrx/Covidien/Medtronic provided funding. Dr. Cotton reported having no relevant disclosures. Three coinvestigators disclosed ties to Pentax Europe, Medtronic, Beamline Diagnostics, C2 Therapeutics, Boston Scientific, and CDx Medical.
Cotton CC et al. Gastroenterology. 2018 Apr 12. doi: 10.1053/j.gastro.2018.04.011.